Cellebrite DI Ltd. (CLBT) vs KLA Corporation (KLAC)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| CLBT | KLAC | |
|---|---|---|
| Sector | Technology | Technology |
| Industry | Software - Infrastructure | Semiconductor Equipment & Materials |
| Size band | MID | LARGE |
| Listing | Nasdaq GS | Nasdaq GS |
| Country | Israel | United States |
| Theme | saas | semiconductor-equipment |
| Price and returns | ||
| Last close | $12.23 | $149.21 |
| Return · 1 week | +9.74% | −10.33% |
| Return · 1 month | +10.48% | −21.12% |
| Return · 3 months | −17.64% | −21.80% |
| Return · year to date | −31.45% | −88.26% |
| Return · 1 year | −33.89% | −87.67% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −38.79% | −92.76% |
| 52-week high | $19.98 | $2,060.08 |
| 52-week low | $9.58 | $144.82 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $3.07B | $194.72B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $30.96M | $1.33B |
| Employees | 1,285 | 17,000 |
| Valuation | ||
| Price to earnings · trailing | 52.61× | 45.28× |
| Price to earnings · forward | 18.52× | 24.59× |
| Price to sales | 5.91× | 15.93× |
| Price to book | 5.64× | 34.12× |
| Enterprise value to EBITDA | 33.35× | 35.97× |
| Enterprise value to revenue | 5.09× | 16.04× |
| PEG ratio | — | 1.58 |
| Earnings per share · trailing | 0.23 | 3.66 |
| Profitability | ||
| Gross margin | 82.96% | 61.30% |
| Operating margin | 5.30% | 42.49% |
| Profit margin | 11.33% | 35.57% |
| Return on equity | 12.42% | 87.50% |
| Return on assets | 3.92% | 20.80% |
| Growth | ||
| Revenue growth | +15.80% | +15.20% |
| Earnings growth | −67.90% | +13.80% |
| Balance sheet and payout | ||
| Debt / equity (%) | 4.32 | 96.88 |
| Current ratio | 1.62 | 2.88 |
| Dividend yield | 0.00% | 0.56% |
| Payout ratio | 0.00% | 21.86% |
| Trend and volatility | ||
| RSI · 14 | 61.35 | 27.35 |
| ADX · 14 | 19.14 | 28.45 |
| 50-day average | $11.41 | $181.34 |
| 200-day average | $13.52 | $891.41 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.17% | 5.37% |
The full CLBT analysis
Everything this table leaves out for Cellebrite DI Ltd.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the CLBT argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full CLBT analysisThe full KLAC analysis
Everything this table leaves out for KLA Corporation: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the KLAC argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full KLAC analysis